These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557 [TBL] [Abstract][Full Text] [Related]
27. Safety of proteasome inhibitors for treatment of multiple myeloma. Schlafer D; Shah KS; Panjic EH; Lonial S Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029 [TBL] [Abstract][Full Text] [Related]
28. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283 [TBL] [Abstract][Full Text] [Related]
29. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886 [TBL] [Abstract][Full Text] [Related]
30. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone. Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Kim A; Seong KM; Kang HJ; Park S; Lee SS Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678 [TBL] [Abstract][Full Text] [Related]
32. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656 [TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics and chemical library screens reveal a novel SCF Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741 [TBL] [Abstract][Full Text] [Related]
34. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma. Findlay S; Nair R; Merrill RA; Kaiser Z; Cajelot A; Aryanpour Z; Heath J; St-Louis C; Papadopoli D; Topisirovic I; St-Pierre J; Sebag M; Kesarwala AH; Hulea L; Taylor EB; Shanmugam M; Orthwein A Blood Adv; 2023 Jul; 7(14):3485-3500. PubMed ID: 36920785 [TBL] [Abstract][Full Text] [Related]
35. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma. Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773 [TBL] [Abstract][Full Text] [Related]
36. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells. Ju D; Xie Y Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315 [TBL] [Abstract][Full Text] [Related]
37. An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma. Li M; Bennett MK; Toubia J; Pope VS; Tea MN; Tamang S; Samuel MS; Anderson PH; Gliddon BL; Powell JA; Pitson SM Br J Haematol; 2024 Feb; 204(2):566-570. PubMed ID: 38053270 [TBL] [Abstract][Full Text] [Related]
38. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A Redox Biol; 2015; 4():23-33. PubMed ID: 25485927 [TBL] [Abstract][Full Text] [Related]
39. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584 [TBL] [Abstract][Full Text] [Related]
40. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation. Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]